Why the study?
Do agents that elevate cAMP levels decrease thrombin binding and response in rabbit and human platelets?
Do agents that elevate cAMP levels decrease thrombin binding and response in rabbit and human platelets?
Increased levels of platelet cAMP are associated with a reduced ability to bind and respond to thrombin, providing mechanistic insight into cAMP-mediated platelet inhibition.
Answers are grounded in this paper and cite their sources.
cAMP-elevating agents may blunt platelet thrombin responses; hypothesis-generating for antiplatelet mechanisms, needs in vivo confirmation.
The effect of high intracellular levels of cAMP on the ability of rabbit and human platelets to bind and respond to thrombin was examined. Control rabbit platelets differed from human platelets in two interesting respects: they showed thrombin-dependent up-regulation of thrombin binding, but also a 3- to 5-fold lower thrombin-binding capacity. Nevertheless, treatment with prostaglandin E1 + theophylline or with forskolin decreased thrombin binding to both rabbit and human platelets by 60 to 70%. This effect was associated with a marked increase in the level of cAMP and seemed to depend on a decrease in number rather than affinity of thrombin-binding sites. Changes in thrombin binding correlated closely with changes in thrombin-stimulated incorporation of 32Pi into phosphatidic acid and a 40-kDa protein. However, regardless of the amount of thrombin that bound to treated platelets, thrombin-stimulated phosphorylation of a 20-kDa protein and serotonin secretion were severely inhibited. Thus, increased levels of platelet cAMP are associated with a reduced ability to bind and respond to thrombin. However, thrombin binding to platelets correlates more closely with some responses than others, presumably because cAMP inhibits additional platelet reactions.
No takes yet. Share an insight, caveat, or question.
Lerea et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: